Jazz Pharmaceuticals plc·4

Mar 9, 5:15 PM ET

Carr Patricia 4

Research Summary

AI-generated summary

Updated

Jazz Pharmaceuticals SVP Patricia Carr Sells 2,723 Shares

What Happened Patricia Carr, SVP and Chief Accounting Officer of Jazz Pharmaceuticals (JAZZ), sold a total of 2,723 ordinary shares in two transactions, generating roughly $503,649 in proceeds. On 2026-03-05, 1,436 shares were transferred/disposed at $186.77 per share (reported as a tax-withholding disposition) for approximately $268,205. On 2026-03-09, 1,287 shares were sold in open-market transactions at a reported weighted average price of $182.94 per share for about $235,444. Both transactions are sales (not purchases).

Key Details

  • Dates and prices:
    • 2026-03-05: 1,436 shares @ $186.77 — $268,205 (Disposition code F: tax withholding)
    • 2026-03-09: 1,287 shares @ $182.94 (weighted avg) — $235,444 (open market sale)
  • Total shares sold: 2,723; total proceeds: ≈ $503,649.
  • Shares owned after the transactions: Not specified in the provided filing excerpt.
  • Footnotes:
    • F1: The 3/5 disposition reflects shares sold to satisfy tax obligations arising from the vesting of previously granted restricted stock units (sell-to-cover).
    • F2: The 3/9 open-market sales were executed in multiple transactions at prices ranging from $186.06 to $186.9115; the filing reports a weighted average and offers to provide transaction-level details on request.
  • Filing timeliness: No late filing flag indicated in the provided information.

Context One sale was a routine tax-withholding sell-to-cover tied to RSU vesting (common and not necessarily a signal about the insider’s view). The other was an open-market sale. Sales by executives can be routine; this Form 4 shows dispositions rather than purchases or option exercises that would increase ownership.